These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 22807098)

  • 81. Effect of renal nerve denervation for resistant hypertension in Thai patients: a report of the first cases series in Thailand.
    Wongpraparut N; Tresukosol D; Roubsantisuk W; Buranakitjaroen P; Chotivoraniyakul C; Pongakasira R
    J Med Assoc Thai; 2014 Mar; 97 Suppl 3():S155-61. PubMed ID: 24772593
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence.
    Persu A; Renkin J; Asayama K; O'Brien E; Staessen JA
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):739-49. PubMed ID: 23750683
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension.
    Ewen S; Mahfoud F; Linz D; Pöss J; Cremers B; Kindermann I; Laufs U; Ukena C; Böhm M
    Hypertension; 2014 Apr; 63(4):839-45. PubMed ID: 24420550
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension.
    Fadl Elmula FE; Jin Y; Yang WY; Thijs L; Lu YC; Larstorp AC; Persu A; Sapoval M; Rosa J; Widimský P; Jacobs L; Renkin J; Petrák O; Chatellier G; Shimada K; Widimský J; Kario K; Azizi M; Kjeldsen SE; Staessen JA;
    Blood Press; 2015; 24(5):263-74. PubMed ID: 26194721
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension.
    Sesa-Ashton G; Nolde JM; Muente I; Carnagarin R; Lee R; Macefield VG; Dawood T; Sata Y; Lambert EA; Lambert GW; Walton A; Kiuchi MG; Esler MD; Schlaich MP
    Hypertension; 2023 Apr; 80(4):811-819. PubMed ID: 36762561
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Updated ESH position paper on interventional therapy of resistant hypertension.
    Schmieder RE; Redon J; Grassi G; Kjeldsen SE; Mancia G; Narkiewicz K; Parati G; Ruilope L; van de Borne P; Tsioufis C;
    EuroIntervention; 2013 May; 9 Suppl R():R58-66. PubMed ID: 23732157
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Does the presence of accessory renal arteries affect the efficacy of renal denervation?
    Id D; Kaltenbach B; Bertog SC; Hornung M; Hofmann I; Vaskelyte L; Sievert H
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1085-91. PubMed ID: 24156968
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effects of renal denervation on ambulatory blood pressure measurements in patients with resistant arterial hypertension.
    Lambert T; Blessberger H; Gammer V; Nahler A; Grund M; Kerschner K; Buchmayr G; Saleh K; Kammler J; Steinwender C
    Clin Cardiol; 2014 May; 37(5):307-11. PubMed ID: 24700288
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Insights on safety and efficacy of renal artery denervation for uncontrolled-resistant hypertension in a high risk population with chronic kidney disease: first Italian real-world experience.
    Marin F; Fezzi S; Gambaro A; Ederle F; Castaldi G; Widmann M; Gangemi C; Ferrero V; Pesarini G; Pighi M; Ribichini FL
    J Nephrol; 2021 Oct; 34(5):1445-1455. PubMed ID: 33481223
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Impact of renal denervation on tissue Na
    Ott C; Kopp C; Dahlmann A; Schmid A; Linz P; Cavallaro A; Hammon M; Ditting T; Veelken R; Uder M; Titze J; Schmieder RE
    Clin Res Cardiol; 2018 Jan; 107(1):42-48. PubMed ID: 28845508
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Renal denervation in patients with resistant hypertension: six-month results.
    Dores H; de Sousa Almeida M; de Araújo Gonçalves P; Branco P; Gaspar A; Sousa H; Canha Gomes A; Andrade MJ; Carvalho MS; Campante Teles R; Raposo L; Mesquita Gabriel H; Pereira Machado F; Mendes M
    Rev Port Cardiol; 2014 Apr; 33(4):197-204. PubMed ID: 24472425
    [TBL] [Abstract][Full Text] [Related]  

  • 93. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
    Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance.
    Ewen S; Cremers B; Meyer MR; Donazzan L; Kindermann I; Ukena C; Helfer AG; Maurer HH; Laufs U; Grassi G; Böhm M; Mahfoud F
    J Hypertens; 2015 Dec; 33(12):2519-25. PubMed ID: 26485463
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.
    Azizi M; Sharp ASP; Fisher NDL; Weber MA; Lobo MD; Daemen J; Lurz P; Mahfoud F; Schmieder RE; Basile J; Bloch MJ; Saxena M; Wang Y; Sanghvi K; Jenkins JS; Devireddy C; Rader F; Gosse P; Claude L; Augustin DA; McClure CK; Kirtane AJ;
    Circulation; 2024 Mar; 149(10):747-759. PubMed ID: 37883784
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Renal sympathetic denervation: effect on ambulatory blood pressure and blood pressure variability in patients with treatment-resistant hypertension. The ReShape CV-risk study.
    Miroslawska A; Solbu M; Skjølsvik E; Toft I; Steigen TK
    J Hum Hypertens; 2016 Mar; 30(3):153-7. PubMed ID: 26134621
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effects of renal sympathetic denervation on cardiac sympathetic activity and function in patients with therapy resistant hypertension.
    van Brussel PM; Eeftinck Schattenkerk DW; Dobrowolski LC; de Winter RJ; Reekers JA; Verberne HJ; Vogt L; van den Born BJ
    Int J Cardiol; 2016 Jan; 202():609-14. PubMed ID: 26447672
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study.
    Mallion JM; Genès N; Vaur L; Clerson P; Vaïsse B; Bobrie G; Chatellier G
    J Hum Hypertens; 2001 Dec; 15(12):841-8. PubMed ID: 11773986
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Expert consensus: renal denervation for the treatment of arterial hypertension.
    Pathak A; Girerd X; Azizi M; Benamer H; Halimi JM; Lantelme P; Lefèvre T; Sapoval M; ; ; ;
    Arch Cardiovasc Dis; 2012; 105(6-7):386-93. PubMed ID: 22977923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.